Business Context and Reporting Period
This Form 8-K is filed by Predictive Oncology Inc. (not Axe Compute Inc.) on July 25, 2024, reporting events occurring on July 25 and July 26, 2024. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol POAI.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $1.26 million from the exercise of existing warrants.
- Shares Issued: 958,117 shares of common stock issued upon warrant exercise.
- Warrant Exercise Price Reduction: Existing warrants originally issued at $14.00 were exercised at a reduced price of $1.32 per share.
- New Warrants Issued:
- Series A Warrants: 958,117 shares, exercise price $1.07, 5-year term.
- Series B Warrants: 958,117 shares, exercise price $1.07, 18-month term.
- Placement Agent Warrants: 67,068 shares, exercise price $1.65, 5-year term.
- Transaction Costs: Fees paid to H.C. Wainwright & Co., LLC included 7.0% cash fee, 1.0% management fee, $35,000 for expenses, and $15,950 for clearing fees.
- Liquidity Context: The company notes an additional $3.58 million in net proceeds raised in May 2024 via an at-the-market facility.
Material Changes and Unusual Items
The primary material change is the inducement of warrant exercises through a significant reduction in the exercise price from $14.00 to $1.32. This transaction resulted in immediate cash inflow but also increased the number of outstanding warrants (Series A and B) with a lower strike price ($1.07), potentially increasing future dilution. The filing does not provide comparative financial metrics (revenue, profit, margins) as this is a current report on a specific transaction rather than a periodic financial statement.
Guidance, Outlook, and Risks
- Use of Proceeds: Net proceeds from this transaction and the May 2024 ATM offering will be used for working capital and general corporate purposes.
- Regulatory Status: The new warrants and underlying shares were issued in a private placement under Section 4(a)(2) and Regulation D. They are unregistered and cannot be sold in the U.S. without an effective registration statement or exemption.
- Registration Obligation: The Company has agreed to file a registration statement covering the resale of shares issuable upon exercise of the new warrants.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 8% total cash fees and other transaction expenses.
- Review the fully diluted share count impact, considering the 958,117 shares issued plus the 1,916,234 shares underlying the new Series A and B warrants.
- Confirm the status of the registration statement for the resale of shares underlying the new warrants.
- Assess the company's cash runway given the combined proceeds of ~$4.84 million (gross) and the stated need for working capital.
- Check for any subsequent filings regarding the May 2024 ATM offering details not fully elaborated in this 8-K.